Christine Mikail Cvijic sold $167k of NGNE
President and CFO at Neurogene Inc.. 4,800 shares at an average of $34.71, traded Jul 1, 2026, filed Jul 2, 2026.
Score components
- +22RoleCFO
- +11Trade size$167k at market
- 0Share of holdings soldSold 5.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001543663-26-000015, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | SOpen-market sale Common Stock10b5-1 | -739 | $34.06 | $25k | 92,901 | Jul 2, 2026 |
| Jul 2, 2026 | SOpen-market sale Common Stock10b5-1 | -2,531 | $34.58 | $88k | 90,370 | Jul 2, 2026 |
| Jul 2, 2026 | SOpen-market sale Common Stock10b5-1 | -1,530 | $35.23 | $54k | 88,840 | Jul 2, 2026 |
Related signals
Other insiders at Neurogene Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $173k 4,800 shares | -5% | |
| 16Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $300k 9,600 shares | -9% | |
| 24Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $55k 2,558 shares | -2% | |
| 10Weak | Neurogene Inc. | Julie Jordan Chief Medical Officer | $18k 828 shares | -6% | |
| 28Weak | Neurogene Inc. | Rachel McMinn Chief Executive Officer | $74k 3,352 shares | -0% | |
| 26Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $141k 6,797 shares | -18% | |
| 26Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $84k 4,045 shares | -4% | |
| 20Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $121k 4,800 shares | -4% | |
| 10Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $103k 6,797 shares | -25% | |
| 10Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $76k 4,501 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.